Medexus Pharmaceuticals (FRA:P731) Cyclically Adjusted Revenue per Share: €3.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:P731 Medexus Pharmaceuticals Inc FRA:P731
59 GF Score
Price €3.06
GF Value €1.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Cyclically Adjusted Revenue per Share?

Medexus Pharmaceuticals FRA:P731 -1.92% 59 Cyclically Adjusted Revenue per Share is €3.01 as of Mar. 2026. GuruFocus rates FRA:P731 with a GF Score™ of 59/100 and a GF Value™ of €1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medexus Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was €0.660. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.01 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medexus Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Medexus Pharmaceuticals was 12.80% per year. The lowest was 11.00% per year. And the median was 11.90% per year.

As of today (2026-07-28), Medexus Pharmaceuticals's current stock price is €3.06. Medexus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €3.01. Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 1.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medexus Pharmaceuticals was 1.04. The lowest was 0.26. And the median was 0.56.


Medexus Pharmaceuticals  (FRA:P731) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.06/3.01
=1.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medexus Pharmaceuticals was 1.04. The lowest was 0.26. And the median was 0.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medexus Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Medexus Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.44 2.54 3.02 3.14 3.01

Medexus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 3.01 3.10 3.08 3.01

FRA:P731 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


FRA:P731
59GF Score
Medexus Pharmaceuticals Inc FRA:P731
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medexus Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.66/132.2623*132.2623
=0.660

Current CPI (Mar. 2026) = 132.2623.

Medexus Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.127 102.002 0.165
201609 0.264 101.765 0.343
201612 0.258 101.449 0.336
201703 0.245 102.634 0.316
201706 0.321 103.029 0.412
201709 0.358 103.345 0.458
201712 0.272 103.345 0.348
201803 0.204 105.004 0.257
201806 0.363 105.557 0.455
201809 0.392 105.636 0.491
201812 0.700 105.399 0.878
201903 0.595 106.979 0.736
201906 0.737 107.690 0.905
201909 0.684 107.611 0.841
201912 0.788 107.769 0.967
202003 1.179 107.927 1.445
202006 1.229 108.401 1.500
202009 1.044 108.164 1.277
202012 1.379 108.559 1.680
202103 0.850 110.298 1.019
202106 0.748 111.720 0.886
202109 0.780 112.905 0.914
202112 0.954 113.774 1.109
202203 0.932 117.646 1.048
202206 1.093 120.806 1.197
202209 1.400 120.648 1.535
202212 1.354 120.964 1.480
202303 1.209 122.702 1.303
202306 1.440 124.203 1.533
202309 1.391 125.230 1.469
202312 0.956 125.072 1.011
202403 0.977 126.258 1.023
202406 1.036 127.522 1.075
202409 0.933 127.285 0.969
202412 1.118 127.364 1.161
202503 0.773 129.181 0.791
202506 0.662 129.892 0.674
202509 0.653 130.287 0.663
202512 0.648 130.366 0.657
202603 0.660 132.262 0.660

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.01 mean?
Medexus Pharmaceuticals (FRA:P731) has a Cyclically Adjusted Revenue per Share of €3.01 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Medexus Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €3.01. Overall, Medexus Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Medexus Pharmaceuticals' Cyclically Adjusted Revenue per Share of €3.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (FRA:P731) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.05, compared to a current price of €3.06 — trading 191.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.01. Medexus Pharmaceuticals' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medexus Pharmaceuticals (FRA:P731), the current Cyclically Adjusted Revenue per Share is €3.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (FRA:P731) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of €3.06 is trading 191.4% above its estimated GF Value™ of €1.05. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:P731:

  • Cyclically Adjusted Revenue per Share: €3.01
  • GF Value™: €1.05 vs. price of €3.06 (191.4% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the FRA:P731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAMDP:Canada
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
59GF Score

Get the complete analysis for FRA:P731

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€1.05
GF Value